Wall Street Zen upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a sell rating to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.
Other equities research analysts have also recently issued reports about the stock. TD Cowen raised their target price on shares of Myriad Genetics from $4.50 to $6.75 and gave the stock a “hold” rating in a research report on Thursday. Wells Fargo & Company set a $4.50 target price on shares of Myriad Genetics in a report on Tuesday, October 20th. UBS Group initiated coverage on shares of Myriad Genetics in a research report on Wednesday, September 9th. They set a “neutral” rating and a $3.60 price target for the company. Stephens dropped their price objective on Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, August 18th. Finally, Craig Hallum upped their price objective on Myriad Genetics from $4.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.55.
Check Out Our Latest Research Report on Myriad Genetics
Myriad Genetics Stock Performance
NASDAQ MYGN opened at $5.92 on Friday. The business’s 50-day moving average price is $4.50 and its 200 day moving average price is $4.62. The company has a current ratio of 1.98, a quick ratio of 1.98 and a debt-to-equity ratio of 0.45. Myriad Genetics has a twelve month low of $2.74 and a twelve month high of $8.09. The company has a market capitalization of $566.25 million, a PE ratio of -4.35 and a beta of 1.62.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.09. Myriad Genetics had a negative return on equity of 19.87% and a negative net margin of 16.07%. The company had revenue of $202.70 million during the quarter, compared to analysts’ expectations of $191.33 million. On average, research analysts predict that Myriad Genetics will post -0.99 earnings per share for the current year.
Institutional Trading of Myriad Genetics
A number of hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new position in shares of Myriad Genetics during the first quarter worth $562,500,000. BlackRock Inc. acquired a new stake in Myriad Genetics during the 2nd quarter valued at $62,184,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Myriad Genetics during the 2nd quarter valued at $8,039,000. Man Group plc purchased a new stake in Myriad Genetics during the 2nd quarter worth $5,189,000. Finally, Bank of America Corp DE purchased a new stake in Myriad Genetics during the 2nd quarter worth $5,150,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.
Key Myriad Genetics News
Here are the key news stories impacting Myriad Genetics this week:
- Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, above analysts’ $191.33 million estimate, and a loss of $0.11 per share—narrower than the expected $0.20 loss. The company also raised the midpoint of its FY2026 revenue outlook to a range of $780 million–$790 million. Article: Myriad Genetics Raises FY26 Revenue Outlook Midpoint
- Positive Sentiment: TD Cowen raised its price target to $6.75 from $4.50, while retaining a Hold rating; Leerink Partners raised its target to $8 from $5, with a Market Perform rating. Higher targets suggest improved expectations, though neither firm upgraded its rating. Article: TD Cowen price target
- Neutral Sentiment: Myriad agreed to sell its Prenatal Health business for $210 million. The proceeds could support the company’s finances and focus, but the divestiture also changes its revenue base; the outlook is presented following the sale. Article: Myriad outlines 2026 outlook following divestiture
- Negative Sentiment: The company said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential exposure of sensitive information or disruption creates uncertainty and could be contributing to investor concern. Article: Myriad reports cybersecurity incident
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.
Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.
Recommended Stories
- Five stocks we like better than Myriad Genetics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
